OBJECTIVES: In low-income settings, treatment failure is often identified using CD4 cell count monitoring. Consequently, patients remain on a failing regimen, resulting in a higher risk of transmission. We investigated the benefit of routine viral load monitoring for reducing HIV transmission. DESIGN: Mathematical model. METHODS: We developed a stochastic mathematical model representing the course of individual viral load, immunological response and survival in a cohort of 1000 HIV-infected patients receiving antiretroviral therapy (ART) in southern Africa. We calculated cohort viral load (CVL; sum of individual viral loads) and used a mathematical relationship between individual viral load values and transmission probability to estimate the number of new HIV infections. Our model was parameterized with data from the International epidemiologic Databases to Evaluate AIDS Southern African collaboration. Sensitivity analyses were performed to assess the validity of the results in a universal 'test and treat' scenario, wherein patients start ART earlier after HIV infection. RESULTS: If CD4 cell count alone was regularly monitored, the CVL was 2.6 × 10 copies/ml and the treated patients transmitted on average 6.3 infections each year. With routine viral load monitoring, both CVL and transmissions were reduced by 31% to 1.7 × 10 copies/ml and 4.3 transmissions, respectively. The relative reduction of 31% between monitoring strategies remained similar for different scenarios. CONCLUSION: Although routine viral load monitoring enhances the preventive effect of ART, the provision of ART to everyone in need should remain the highest priority.
OBJECTIVES: In low-income settings, treatment failure is often identified using CD4 cell count monitoring. Consequently, patients remain on a failing regimen, resulting in a higher risk of transmission. We investigated the benefit of routine viral load monitoring for reducing HIV transmission. DESIGN: Mathematical model. METHODS: We developed a stochastic mathematical model representing the course of individual viral load, immunological response and survival in a cohort of 1000 HIV-infectedpatients receiving antiretroviral therapy (ART) in southern Africa. We calculated cohort viral load (CVL; sum of individual viral loads) and used a mathematical relationship between individual viral load values and transmission probability to estimate the number of new HIV infections. Our model was parameterized with data from the International epidemiologic Databases to Evaluate AIDS Southern African collaboration. Sensitivity analyses were performed to assess the validity of the results in a universal 'test and treat' scenario, wherein patients start ART earlier after HIV infection. RESULTS: If CD4 cell count alone was regularly monitored, the CVL was 2.6 × 10 copies/ml and the treated patients transmitted on average 6.3 infections each year. With routine viral load monitoring, both CVL and transmissions were reduced by 31% to 1.7 × 10 copies/ml and 4.3 transmissions, respectively. The relative reduction of 31% between monitoring strategies remained similar for different scenarios. CONCLUSION: Although routine viral load monitoring enhances the preventive effect of ART, the provision of ART to everyone in need should remain the highest priority.
Authors: Rebecca Bunnell; John Paul Ekwaru; Peter Solberg; Nafuna Wamai; Winnie Bikaako-Kajura; Willy Were; Alex Coutinho; Cheryl Liechty; Elizabeth Madraa; George Rutherford; Jonathan Mermin Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Marieke Pingen; Monique Nijhuis; Johan A de Bruijn; Charles A B Boucher; Annemarie M J Wensing Journal: J Antimicrob Chemother Date: 2011-04-18 Impact factor: 5.790
Authors: Matthias Egger; Didier K Ekouevi; Carolyn Williams; Rita Elias Lyamuya; Henri Mukumbi; Paula Braitstein; Tyler Hartwell; Claire Graber; Benjamin H Chi; Andrew Boulle; François Dabis; Kara Wools-Kaloustian Journal: Int J Epidemiol Date: 2011-05-18 Impact factor: 7.196
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Edward J Mills; Celestin Bakanda; Josephine Birungi; Keith Chan; Nathan Ford; Curtis L Cooper; Jean B Nachega; Mark Dybul; Robert S Hogg Journal: Ann Intern Med Date: 2011-07-18 Impact factor: 25.391
Authors: A N Phillips; S Staszewski; R Weber; O Kirk; P Francioli; V Miller; P Vernazza; J D Lundgren; B Ledergerber Journal: JAMA Date: 2001-11-28 Impact factor: 56.272
Authors: Stephen T Wright; Andrew Carr; Ian Woolley; Michelle Giles; Jennifer Hoy; David A Cooper; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2011-09-01 Impact factor: 3.731
Authors: Olivia Keiser; Benjamin H Chi; Thomas Gsponer; Andrew Boulle; Catherine Orrell; Sam Phiri; Nicola Maxwell; Mhairi Maskew; Hans Prozesky; Matthew P Fox; Andrew Westfall; Matthias Egger Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Kimberly A Powers; Azra C Ghani; William C Miller; Irving F Hoffman; Audrey E Pettifor; Gift Kamanga; Francis Ea Martinson; Myron S Cohen Journal: Lancet Date: 2011-07-16 Impact factor: 79.321
Authors: Luisa Salazar-Vizcaya; Olivia Keiser; Mary-Ann Davies; Andreas D Haas; Nello Blaser; Vivian Cox; Brian Eley; Helena Rabie; Harry Moultrie; Janet Giddy; Robin Wood; Matthias Egger; Janne Estill Journal: AIDS Date: 2014-10-23 Impact factor: 4.177
Authors: Andrew Phillips; Amir Shroufi; Lara Vojnov; Jennifer Cohn; Teri Roberts; Tom Ellman; Kimberly Bonner; Christine Rousseau; Geoff Garnett; Valentina Cambiano; Fumiyo Nakagawa; Deborah Ford; Loveleen Bansi-Matharu; Alec Miners; Jens D Lundgren; Jeffrey W Eaton; Rosalind Parkes-Ratanshi; Zachary Katz; David Maman; Nathan Ford; Marco Vitoria; Meg Doherty; David Dowdy; Brooke Nichols; Maurine Murtagh; Meghan Wareham; Kara M Palamountain; Christine Chakanyuka Musanhu; Wendy Stevens; David Katzenstein; Andrea Ciaranello; Ruanne Barnabas; R Scott Braithwaite; Eran Bendavid; Kusum J Nathoo; David van de Vijver; David P Wilson; Charles Holmes; Anna Bershteyn; Simon Walker; Elliot Raizes; Ilesh Jani; Lisa J Nelson; Rosanna Peeling; Fern Terris-Prestholt; Joseph Murungu; Tsitsi Mutasa-Apollo; Timothy B Hallett; Paul Revill Journal: Nature Date: 2015-12-03 Impact factor: 49.962
Authors: Janne Estill; Matthias Egger; Nello Blaser; Luisa Salazar Vizcaya; Daniela Garone; Robin Wood; Jennifer Campbell; Timothy B Hallett; Olivia Keiser Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Maya L Petersen; Linh Tran; Elvin H Geng; Steven J Reynolds; Andrew Kambugu; Robin Wood; David R Bangsberg; Constantin T Yiannoutsos; Steven G Deeks; Jeffrey N Martin Journal: AIDS Date: 2014-09-10 Impact factor: 4.177
Authors: Janne Estill; Nathan Ford; Luisa Salazar-Vizcaya; Andreas D Haas; Nello Blaser; Vincent Habiyambere; Olivia Keiser Journal: Lancet HIV Date: 2016-02-16 Impact factor: 12.767
Authors: Daniel Keebler; Paul Revill; Scott Braithwaite; Andrew Phillips; Nello Blaser; Annick Borquez; Valentina Cambiano; Andrea Ciaranello; Janne Estill; Richard Gray; Andrew Hill; Olivia Keiser; Jason Kessler; Nicolas A Menzies; Kimberly A Nucifora; Luisa Salazar Vizcaya; Simon Walker; Alex Welte; Philippa Easterbrook; Meg Doherty; Gottfried Hirnschall; Timothy B Hallett Journal: Lancet Glob Health Date: 2013-12-10 Impact factor: 26.763